Transcription Factor NF-κB Differentially Regulates Death Receptor 5 Expression Involving Histone Deacetylase 1

REFERENCES

• Aron, J. L., M. R. Parthun, G. Marcucci, S. Kitada, A. P. Mone, M. E. Davis, T. Shen, T. Murphy, J. Wickham, C. Kanakry, D. M. Lucas, J. C. Reed, M. R. Grever, and J. C. Byrd. 2003. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 102:652–658.
   PubMed Web of Science ®Google Scholar
• Ashburner, B. P., S. D. Westerheide, and A. S. Baldwin, Jr. 2001. The p65 (RelA) subunit of NF-κB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell. Biol. 21:7065–7077.
   PubMed Web of Science ®Google Scholar
• Ashkenazi, A., and V. M. Dixit. 1998. Death receptors: signaling and modulation. Science 281:1305–1308.
   PubMed Web of Science ®Google Scholar
• Baldwin, A. S. 2001. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J. Clin. Investig. 107:241–246.
   PubMed Web of Science ®Google Scholar
• Baldwin, A. S., Jr. 1996. The NF-κB and IκB proteins: new discoveries and insights. Annu. Rev. Immunol. 14:649–683.
   PubMed Web of Science ®Google Scholar
• Bodmer, J. L., N. Holler, S. Reynard, P. Vinciguerra, P. Schneider, P. Juo, J. Blenis, and J. Tschopp. 2000. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat. Cell Biol. 2:241–243.
   PubMed Web of Science ®Google Scholar
• Campbell, K. J., S. Rocha, and N. D. Perkins. 2004. Active repression of antiapoptotic gene expression by RelA(p65) NF-κB. Mol. Cell 13:853–865.
   PubMed Web of Science ®Google Scholar
• Chen, X., K. Kandasamy, and R. K. Srivastava. 2003. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor κB in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res. 63:1059–1066.
   PubMed Web of Science ®Google Scholar
• Ghosh, S., and M. Karin. 2002. Missing pieces in the NF-κB puzzle. Cell 109(Suppl.):S81–S96.
   PubMed Web of Science ®Google Scholar
• Ghosh, S., M. J. May, and E. B. Kopp. 1998. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16:225–260.
   PubMed Web of Science ®Google Scholar
• Gibson, S. B., R. Oyer, A. C. Spalding, S. M. Anderson, and G. L. Johnson. 2000. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol. Cell. Biol. 20:205–212.
   PubMed Web of Science ®Google Scholar
• Gray, S. G., and B. T. Teh. 2001. Histone acetylation/deacetylation and cancer: an “open” and “shut” case. Curr. Mol. Med. 1:401–429.
   PubMedGoogle Scholar
• Gregory, P. D., K. Wagner, and W. Horz. 2001. Histone acetylation and chromatin remodeling. Exp. Cell Res. 265:195–202.
   PubMed Web of Science ®Google Scholar
• Griffith, T. S., W. A. Chin, G. C. Jackson, D. H. Lynch, and M. Z. Kubin. 1998. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 161:2833–2840.
   PubMed Web of Science ®Google Scholar
• Grimm, S., M. K. Bauer, P. A. Baeuerle, and K. Schulze-Osthoff. 1996. Bcl-2 down-regulates the activity of transcription factor NF-κB induced upon apoptosis. J. Cell Biol. 134:13–23.
   PubMed Web of Science ®Google Scholar
• Henson, E. S., E. M. Gibson, J. Villanueva, N. A. Bristow, N. Haney, and S. B. Gibson. 2003. Increased expression of Mcl-1 is responsible for the blockage of TRAIL-induced apoptosis mediated by EGF/ErbB1 signaling pathway. J. Cell. Biochem. 89:1177–1192.
   PubMedGoogle Scholar
• Higuchi, H., A. Grambihler, A. Canbay, S. F. Bronk, and G. J. Gores. 2004. Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. J. Biol. Chem. 279:51–60.
   PubMed Web of Science ®Google Scholar
• Hockenbery, D. M., Z. N. Oltvai, X. M. Yin, C. L. Milliman, and S. J. Korsmeyer. 1993. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75:241–251.
   PubMed Web of Science ®Google Scholar
• Ichikawa, K., W. Liu, L. Zhao, Z. Wang, D. Liu, T. Ohtsuka, H. Zhang, J. D. Mountz, W. J. Koopman, R. P. Kimberly, and T. Zhou. 2001. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7:954–960.
   PubMed Web of Science ®Google Scholar
• Johnston, J. B., A. F. Kabore, J. Strutinsky, X. Hu, J. T. Paul, D. M. Kropp, B. Kuschak, A. Begleiter, and S. B. Gibson. 2003. Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia. Oncogene 22:8356–8369.
   PubMed Web of Science ®Google Scholar
• Keane, M. M., S. A. Ettenberg, M. M. Nau, E. K. Russell, and S. Lipkowitz. 1999. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 59:734–741.
   PubMed Web of Science ®Google Scholar
• Kramer, O. H., M. Gottlicher, and T. Heinzel. 2001. Histone deacetylase as a therapeutic target. Trends Endocrinol. Metab. 12:294–300.
   PubMed Web of Science ®Google Scholar
• Kreuz, S., D. Siegmund, P. Scheurich, and H. Wajant. 2001. NF-κB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol. Cell. Biol. 21:3964–3973.
   PubMed Web of Science ®Google Scholar
• Mahlknecht, U., and D. Hoelzer. 2000. Histone acetylation modifiers in the pathogenesis of malignant disease. Mol. Med. 6:623–644.
   PubMed Web of Science ®Google Scholar
• Marks, P., R. A. Rifkind, V. M. Richon, R. Breslow, T. Miller, and W. K. Kelly. 2001. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1:194–202.
   PubMed Web of Science ®Google Scholar
• Marks, P. A., V. M. Richon, R. Breslow, and R. A. Rifkind. 2001. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13:477–483.
   PubMed Web of Science ®Google Scholar
• Mayo, M. W., C. Y. Wang, P. C. Cogswell, K. S. Rogers-Graham, S. W. Lowe, C. J. Der, and A. S. Baldwin, Jr. 1997. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 278:1812–1815.
   PubMed Web of Science ®Google Scholar
• Meng, R. D., E. R. McDonald III, M. S. Sheikh, A. J. Fornace, Jr., and W. S. El-Deiry. 2000. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol. Ther. 1:130–144.
   PubMed Web of Science ®Google Scholar
• Nakata, S., T. Yoshida, M. Horinaka, T. Shiraishi, M. Wakada, and T. Sakai. 2004. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23:6261–6271.
   PubMed Web of Science ®Google Scholar
• Nebbioso, A., N. Clarke, E. Voltz, E. Germain, C. Ambrosino, P. Bontempo, R. Alvarez, E. M. Schiavone, F. Ferrara, F. Bresciani, A. Weisz, A. R. de Lera, H. Gronemeyer, and L. Altucci. 2005. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 11:77–84.
   PubMed Web of Science ®Google Scholar
• Obeid, L. M., C. M. Linardic, L. A. Karolak, and Y. A. Hannun. 1993. Programmed cell death induced by ceramide. Science 259:1769–1771.
   PubMed Web of Science ®Google Scholar
• Osborn, L., S. Kunkel, and G. J. Nabel. 1989. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB. Proc. Natl. Acad. Sci. USA 86:2336–2340.
   PubMed Web of Science ®Google Scholar
• Pan, G., K. O'Rourke, A. M. Chinnaiyan, R. Gentz, R. Ebner, J. Ni, and V. M. Dixit. 1997. The receptor for the cytotoxic ligand TRAIL. Science 276:111–113.
   PubMed Web of Science ®Google Scholar
• Ravi, R., G. C. Bedi, L. W. Engstrom, Q. Zeng, B. Mookerjee, C. Gelinas, E. J. Fuchs, and A. Bedi. 2001. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB. Nat. Cell Biol. 3:409–416.
   PubMed Web of Science ®Google Scholar
• Rosato, R. R., J. A. Almenara, Y. Dai, and S. Grant. 2003. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. 2:1273–1284.
   PubMed Web of Science ®Google Scholar
• Ryan, K. M., M. K. Ernst, N. R. Rice, and K. H. Vousden. 2000. Role of NF-κB in p53-mediated programmed cell death. Nature 404:892–897.
   PubMed Web of Science ®Google Scholar
• Schreck, R., P. Rieber, and P. A. Baeuerle. 1991. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J. 10:2247–2258.
   PubMed Web of Science ®Google Scholar
• Schulze-Osthoff, K., D. Ferrari, M. Los, S. Wesselborg, and M. E. Peter. 1998. Apoptosis signaling by death receptors. Eur. J. Biochem. 254:439–459.
   PubMedGoogle Scholar
• Schutze, S., K. Potthoff, T. Machleidt, D. Berkovic, K. Wiegmann, and M. Kronke. 1992. TNF activates NF-κB by phosphatidylcholine-specific phospholipase C-induced “acidic” sphingomyelin breakdown. Cell 71:765–776.
   PubMed Web of Science ®Google Scholar
• Screaton, G. R., J. Mongkolsapaya, X. N. Xu, A. E. Cowper, A. J. McMichael, and J. I. Bell. 1997. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr. Biol. 7:693–696.
   PubMed Web of Science ®Google Scholar
• Sheridan, J. P., S. A. Marsters, R. M. Pitti, A. Gurney, M. Skubatch, D. Baldwin, L. Ramakrishnan, C. L. Gray, K. Baker, W. I. Wood, A. D. Goddard, P. Godowski, and A. Ashkenazi. 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818–821.
   PubMed Web of Science ®Google Scholar
• Shetty, S., J. B. Gladden, E. S. Henson, X. Hu, J. Villanueva, N. Haney, and S. B. Gibson. 2002. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFκB activation in epithelial derived cell lines. Apoptosis 7:413–420.
   PubMed Web of Science ®Google Scholar
• Singh, T. R., S. Shankar, X. Chen, M. Asim, and R. K. Srivastava. 2003. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res. 63:5390–5400.
   PubMed Web of Science ®Google Scholar
• Spencer, V. A., J. M. Sun, L. Li, and J. R. Davie. 2003. Chromatin immunoprecipitation: a tool for studying histone acetylation and transcription factor binding. Methods 31:67–75.
   PubMed Web of Science ®Google Scholar
• Srivastava, R. K. 2001. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 3:535–546.
   PubMed Web of Science ®Google Scholar
• Strahl, B. D., and C. D. Allis. 2000. The language of covalent histone modifications. Nature 403:41–45.
   PubMed Web of Science ®Google Scholar
• Suliman, A., A. Lam, R. Datta, and R. K. Srivastava. 2001. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 20:2122–2133.
   PubMed Web of Science ®Google Scholar
• Takimoto, R., and W. S. El-Deiry. 2000. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 19:1735–1743.
   PubMed Web of Science ®Google Scholar
• Tergaonkar, V., M. Pando, O. Vafa, G. Wahl, and I. Verma. 2002. p53 stabilization is decreased upon NFκB activation: a role for NFκB in acquisition of resistance to chemotherapy. Cancer Cell 1:493–503.
   PubMed Web of Science ®Google Scholar
• Timmermann, S., H. Lehrmann, A. Polesskaya, and A. Harel-Bellan. 2001. Histone acetylation and disease. Cell. Mol. Life Sci. 58:728–736.
   PubMed Web of Science ®Google Scholar
• Urnov, F. D., E. J. Rebar, A. Reik, and P. P. Pandolfi. 2002. Designed transcription factors as structural, functional and therapeutic probes of chromatin in vivo. Fourth in review series on chromatin dynamics. EMBO Rep. 3:610–615.
   PubMedGoogle Scholar
• Wadgaonkar, R., K. M. Phelps, Z. Haque, A. J. Williams, E. S. Silverman, and T. Collins. 1999. CREB-binding protein is a nuclear integrator of nuclear factor-κB and p53 signaling. J. Biol. Chem. 274:1879–1882.
   PubMed Web of Science ®Google Scholar
• Walczak, H., M. A. Degli-Esposti, R. S. Johnson, P. J. Smolak, J. Y. Waugh, N. Boiani, M. S. Timour, M. J. Gerhart, K. A. Schooley, C. A. Smith, R. G. Goodwin, and C. T. Rauch. 1997. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16:5386–5397.
   PubMed Web of Science ®Google Scholar
• Walczak, H., R. E. Miller, K. Ariail, B. Gliniak, T. S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, C. Smith, P. Smolak, R. G. Goodwin, C. T. Rauch, J. C. Schuh, and D. H. Lynch. 1999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5:157–163.
   PubMed Web of Science ®Google Scholar
• Wang, C. Y., M. W. Mayo, R. G. Korneluk, D. V. Goeddel, and A. S. Baldwin, Jr. 1998. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281:1680–1683.
   PubMed Web of Science ®Google Scholar
• Wang, S., and W. S. El-Deiry. 2004. Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res. 64:6666–6672.
   PubMed Web of Science ®Google Scholar
• Webster, G. A., and N. D. Perkins. 1999. Transcriptional cross talk between NF-κB and p53. Mol. Cell. Biol. 19:3485–3495.
   PubMed Web of Science ®Google Scholar
• Wu, G. S., T. F. Burns, E. R. McDonald III, W. Jiang, R. Meng, I. D. Krantz, G. Kao, D. D. Gan, J. Y. Zhou, R. Muschel, S. R. Hamilton, N. B. Spinner, S. Markowitz, G. Wu, and W. S. el-Deiry. 1997. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet 17:141–143.
   PubMed Web of Science ®Google Scholar
• Wu, M. X., Z. Ao, K. V. Prasad, R. Wu, and S. F. Schlossman. 1998. IEX-1L, an apoptosis inhibitor involved in NF-κB-mediated cell survival. Science 281:998–1001.
   PubMed Web of Science ®Google Scholar
• Yoshida, T., A. Maeda, N. Tani, and T. Sakai. 2001. Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS Lett. 507:381–385.
   PubMed Web of Science ®Google Scholar
• Zhao, H., L. L. Hart, U. Keller, L. T. Holth, and J. R. Davie. 2002. Characterization of stably transfected fusion protein GFP-estrogen receptor-alpha in MCF-7 human breast cancer cells. J. Cell. Biochem. 86:365–375.
   PubMedGoogle Scholar
• Zhong, H., M. J. May, E. Jimi, and S. Ghosh. 2002. The phosphorylation status of nuclear NF-κ B determines its association with CBP/p300 or HDAC-1. Mol. Cell 9:625–636.
   PubMed Web of Science ®Google Scholar